The rapid spread of novel SARS-CoV-2 across the globe has become a significant threat to humankind ([@bib0025]). Since the emergence of SARS-CoV-2, the emphasis on combatting the COVID-19 pandemic focused on social distancing and lockdown of cities to avoid medical care bottlenecks and to spread-out critical care over time. However, the escalating death toll in some countries when compared with others is alarming ([@bib0030]). Several factors, including but not limited to, age and comorbid health conditions, have been significantly linked to higher fatalities, especially in Italy ([@bib0010]). Such differences in fatality rates could be linked to genetic variations in SARS-CoV-2, but the literature about this is lacking.

Currently, complete SARS-CoV-2 sequences using NGS technology are being deposited at GISAID ([@bib0020]). These sequences are being extensively scrutinized to understand their transmission, evolutionary and genetic relationships through phylogeny ([@bib0005]). However, it is unclear whether the SARS-CoV-2 genetic mutations influence its transmissibility and/or its virulence, which could account for higher fatalities in some countries. Here, we utilized the phylogenetic tree of 4,246 SARS-CoV-2 genomes obtained from GISAID ([@bib0020]) and predict a possible link between higher fatalities and SARS-CoV-2 codon 614 in Spike protein (S), which replaces Aspartic acid (D) with Glycine (G) at this site. The SARS-CoV-2 genomes with the S-D614G variant have been classified under a larger phylogenetic clade G constituting most strains from Europe ([Figure 1](#fig0005){ref-type="fig"} A) ([@bib0020], [@bib0005]). Notably, mutations in the S protein likely induce conformational modifications that alter antigenicity ([@bib0015]), plausibly by mimicking the open status and facilitate the exposure of the cleavage domain to proteases, *FURIN*, or *TMPRSS2*, and could be sufficient to speed up the cleavage ([Figure 2](#fig0010){ref-type="fig"} ).Figure 1**(A)** Unrooted phylogenetic tree with clear distinction of the 614G and 614D clades at the S protein site (<https://nextstrain.org/ncov>; last accessed May 2, 2020). **(B)** Bar plot showing the total number of deaths per million populaces (<https://www.worldometers.info/coronavirus/>; last accessed May 2, 2020). The map inside the box plot presents the distribution of S-614G and the wild-type S-614D in European populations (<https://nextstrain.org/ncov>; last accessed May 2, 2020) labeled in the y-axis of the bar plot.Figure 1Figure 2The mutation observed at the S protein of the SARS-COV-2, D614G in white color, may create conformational changes mimicking the open status and facilitate the cleavage domain's exposure to proteases *FURIN* or *TMPRSS2* and could be sufficient to speed up the cleavage.Figure 2

Strikingly, we observed that the variant S-D614G distinguishes the SARS-CoV-2 strains ([Figure 1](#fig0005){ref-type="fig"}A) that may have caused fatal infections in European populations ([Figure 1](#fig0005){ref-type="fig"}B). For example, a substantial number of strains with the S-D614G variant are from the countries Belgium, Spain, Italy, France, Netherlands, and Switzerland that top the death toll ([Figure 1](#fig0005){ref-type="fig"}B) (<https://www.worldometers.info/coronavirus/>; last accessed May 2, 2020); while Germany and Kuwait, with a lower death toll, constitute most strains with the wild-type 614D at S ([Figure 1](#fig0005){ref-type="fig"}B). It is also important to note that this scenario in Germany and other European countries remains uncertain as the number of cases is increasing every day. Therefore, continuous assessment and follow-up will be crucial to contain the virus.

Overall, our observation speculates that the S-D614G strains may be more virulent, increasing the severity in infected individuals, especially in Europe where this mutation is prominent. While our evidence is circumstantial, examining the amino acid 614 at S protein site (or other mutations) in mildly ill patients versus critically ill patients may be an asset in our arsenal against COVID-19. In the absence of any experimental studies, our interpretation with limited data will hopefully be helpful for researchers, at this time.
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